Cv Sciences Inc Revenue Growth Rates (CVSI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cv Sciences Inc   (CVSI)
 

CVSI's Revenue Growth by Quarter and Year

Cv Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CVSI Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 2.99
1st Quarter March 3.20
FY 6.19

CVSIs Annual Revenue
Cv Sciences Inc 's Revenue in the fiscal year 2025 $ 13.79 millions
Cv Sciences Inc 's Revenue in the fiscal year 2024 $ 15.17 millions
Cv Sciences Inc 's Revenue in the fiscal year 2023 $ 15.09 millions
Cv Sciences Inc 's Revenue in the fiscal year 2022 $ 16.21 millions
Cv Sciences Inc 's Revenue in the fiscal year 2021 $ 20.05 millions




CVSI Revenue second quarter 2025 Y/Y Growth Comment
Cv Sciences Inc reported Revenue growth of 5.11% year on year in the second quarter 2025, to $ 2.99 millions, this is lower than Cv Sciences Inc 's recent average Revenue rise of 95.03%.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 133 other companies have achieved higher Revenue growth. While Cv Sciences Inc ' s Revenue increase of 5.11% ranks overall at the positon no. 2172 in the second quarter 2025.


CVSI Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - -10.05 % 8.88 % -12.66 %
3rd Quarter September - -31.75 % -1.56 % 2.4 %
2nd Quarter June 5.11 % -26.42 % 3.76 % -10.14 %
1st Quarter March 20.3 % -30.91 % -7.23 % -6.74 %
FY   - -24.92 % 0.53 % -

Financial Statements
Cv Sciences Inc 's second quarter 2025 Revenue $ 2.99 millions CVSI's Income Statement
Cv Sciences Inc 's second quarter 2024 Revenue $ 2.84 millions Quarterly CVSI's Income Statement


CVSI Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 28.29 % -2.65 % -11.98 %
3rd Quarter September - -9.15 % -2.07 % 3.23 %
2nd Quarter June -6.72 % 6.77 % 0.26 % -10.36 %
1st Quarter March -3.32 % -27.72 % 13.91 % 7.24 %
FY (Year on Year)   - -24.92 % 0.53 % -


Back to CVSI Growth rate Comparisons >> Back to CVSI Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #342
Overall #2172

Revenue Y/Y Growth Statistics
High Average Low
2691.33 % 95.03 % -67.98 %
(Dec 31 2014)   (Mar 31 2021)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #342
Overall #2172
Revenue Y/Y Growth Statistics
High Average Low
2691.33 % 95.03 % -67.98 %
(Dec 31 2014)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Cv Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
389.02 % 13.22 % -90.05 %
(Dec 31 2013)  


CVSI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Cv Sciences Inc disclosed decline in Revenue from the first quarter by -6.72% to $ 2.99 millions, from $ 3.20 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2025 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 158 other companies have achieved higher Revenue quarter on quarter growth. While Cv Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3301.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #457
Overall #3301
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #457
Overall #3301
Revenue Q/Q Growth Statistics
High Average Low
389.02 % 13.22 % -90.05 %
(Dec 31 2013)  


CVSI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Cv Sciences Inc disclosed decline in Revenue from the first quarter by -6.72% to $ 2.99 millions, from $ 3.20 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2025 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 158 other companies have achieved higher Revenue quarter on quarter growth. While Cv Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3301.


Cv Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 12.07 $ 11.92 $ 11.39 $ 11.76 $ 12.96
Y / Y Revenue Growth (TTM) -6.88 % -14.66 % -24.92 % -20.91 % -13.23 %
Year on Year Revenue Growth Overall Ranking # 3289 # 2633 # 1841 # 2123 # 2559
Seqeuential Revenue Change (TTM) 1.18 % 4.72 % -3.15 % -9.25 % -7.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 3051 # 2296 # 1603 # 1797 # 2201


Cumulative Revenue growth Comment
Cv Sciences Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Cv Sciences Inc 's annual Revenue decrease would be -6.88% year on year to $12 millions.

In the Healthcare sector 442 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2633 to 3289.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 141
Healthcare Sector # 443
Overall # 3289

Revenue TTM Y/Y Growth Statistics
High Average Low
373.09 %
 24.54 %
-55.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 141
Sector # 414
S&P 500 # 3051
Cumulative Revenue growth Comment
Cv Sciences Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Cv Sciences Inc 's annual Revenue drop would be -6.88% year on year to $12 millions.

In the Healthcare sector 442 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2633 to 3289.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 141
Healthcare Sector # 443
Overall # 3289

Revenue TTM Y/Y Growth Statistics
High Average Low
373.09 %
24.54 %
-55.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 141
Sector # 414
S&P 500 # 3051




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CVSI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
National Healthcare Corp8.83%$ 8.833 millions
Chemed Corporation8.80%$ 8.800 millions
Tactile Systems Technology Inc 8.76%$ 8.763 millions
Gyre Therapeutics Inc 8.72%$ 8.718 millions
P3 Health Partners Inc 8.60%$ 8.599 millions
Maravai Lifesciences Holdings Inc 8.53%$ 8.534 millions
U S Physical Therapy Inc8.47%$ 8.470 millions
Ocugen Inc 8.38%$ 8.376 millions
Baxter International Inc 8.36%$ 8.363 millions
Carlisle Companies Incorporated8.33%$ 8.334 millions
Universal Health Services Inc 8.27%$ 8.268 millions
Addus Homecare Corp8.18%$ 8.181 millions
Puma Biotechnology Inc 7.75%$ 7.754 millions
Cryoport inc 7.74%$ 7.737 millions
Schrodinger Inc 7.54%$ 7.542 millions
Boston Scientific Corporation7.53%$ 7.528 millions
Agilon Health Inc 7.15%$ 7.151 millions
Tenet Healthcare Corp6.77%$ 6.773 millions
Henry Schein Inc 6.73%$ 6.728 millions
Collegium Pharmaceutical Inc 6.67%$ 6.668 millions
Mallinckrodt Plc6.62%$ 6.617 millions
Johnson and Johnson6.60%$ 6.600 millions
Prestige Consumer Healthcare Inc 6.57%$ 6.569 millions
Msa Safety Inc6.25%$ 6.252 millions
Pacira Biosciences inc 6.24%$ 6.240 millions
Globus Medical Inc 5.94%$ 5.940 millions
Labcorp Holdings Inc 5.78%$ 5.778 millions
Tandem Diabetes Care Inc 5.77%$ 5.768 millions
Bristol myers Squibb Company5.74%$ 5.738 millions
Haemonetics Corporation5.65%$ 5.646 millions


About Cv Sciences Inc Revenue Growth Rates (CVSI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cv Sciences Inc (CIK 1510964).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-349211
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cv Sciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.